Safety of adalimumab and predictors of adverse events in 1693 Japanese patients with Crohn's disease

Haruhiko Ogata, Mamoru Watanabe, Toshiyuki Matsui, Hidenori Hase, Motohiro Okayasu, Tsuyoshi Tsuchiya, Yasuhiko Shinmura, Toshifumi Hibi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background and Aims: Data from an all-cases post-marketing study were used to evaluate the safety and effectiveness of adalimumab in Japanese patients with Crohn's disease [CD]. Methods: Patients received adalimumab for 24 weeks. Data from all patients [n = 1693] were used for the safety assessment. Data from patients with CD activity index [CDAI] ≥ 150 at baseline were used for the effectiveness assessment. Results: The most frequent serious adverse drug reaction [ADR] was infection and infestations [6.6 events/100 patient-years]. The risk of serious infections increased in patients who had a history of malignancy and those with concomitant corticosteroid use. Of 415 patients who had switched from another anti-tumour necrosis factor alpha [TNFα] agent to adalimumab due to ADRs, 7.2% discontinued due to ADRs to adalimumab. Ten of 13 patients with a history of tuberculosis [TB] received prophylactic medication, and none developed TB. TB developed in one patient with no history of TB or anti-TB prophylaxis. Remission rates were 41.3% and 32.4% at 4 and 24 weeks, respectively. Remission rates did not differ between patients with and without concomitant use of immunomodulators. Predictive variables for increased effectiveness were CDAI ≤ 220 and disease duration of ≤ 2 years. Perianal lesions and loss of response to previous anti-TNFα agents affected effectiveness. Conclusions: The most frequent serious ADR was infection. Adalimumab significantly reduced disease activity, without any unexpected ADRs. Development of active TB during adalimumab therapy can be prevented through TB screening and prophylaxis. In patients who switched from another anti-TNFα agent to adalimumab due to ADRs, adalimumab was well tolerated.

Original languageEnglish
Pages (from-to)1033-1041
Number of pages9
JournalJournal of Crohn's and Colitis
Volume10
Issue number9
DOIs
Publication statusPublished - 2016

Fingerprint

Crohn Disease
Safety
Tuberculosis
Tumor Necrosis Factor-alpha
Drug-Related Side Effects and Adverse Reactions
Adalimumab
Infection
Immunologic Factors
Marketing
Adrenal Cortex Hormones

Keywords

  • Adalimumab
  • Crohn's disease
  • Post-marketing study

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Safety of adalimumab and predictors of adverse events in 1693 Japanese patients with Crohn's disease. / Ogata, Haruhiko; Watanabe, Mamoru; Matsui, Toshiyuki; Hase, Hidenori; Okayasu, Motohiro; Tsuchiya, Tsuyoshi; Shinmura, Yasuhiko; Hibi, Toshifumi.

In: Journal of Crohn's and Colitis, Vol. 10, No. 9, 2016, p. 1033-1041.

Research output: Contribution to journalArticle

Ogata, H, Watanabe, M, Matsui, T, Hase, H, Okayasu, M, Tsuchiya, T, Shinmura, Y & Hibi, T 2016, 'Safety of adalimumab and predictors of adverse events in 1693 Japanese patients with Crohn's disease', Journal of Crohn's and Colitis, vol. 10, no. 9, pp. 1033-1041. https://doi.org/10.1093/ecco-jcc/jjw060
Ogata, Haruhiko ; Watanabe, Mamoru ; Matsui, Toshiyuki ; Hase, Hidenori ; Okayasu, Motohiro ; Tsuchiya, Tsuyoshi ; Shinmura, Yasuhiko ; Hibi, Toshifumi. / Safety of adalimumab and predictors of adverse events in 1693 Japanese patients with Crohn's disease. In: Journal of Crohn's and Colitis. 2016 ; Vol. 10, No. 9. pp. 1033-1041.
@article{605b860b02dd4f97ab2958f1573cb247,
title = "Safety of adalimumab and predictors of adverse events in 1693 Japanese patients with Crohn's disease",
abstract = "Background and Aims: Data from an all-cases post-marketing study were used to evaluate the safety and effectiveness of adalimumab in Japanese patients with Crohn's disease [CD]. Methods: Patients received adalimumab for 24 weeks. Data from all patients [n = 1693] were used for the safety assessment. Data from patients with CD activity index [CDAI] ≥ 150 at baseline were used for the effectiveness assessment. Results: The most frequent serious adverse drug reaction [ADR] was infection and infestations [6.6 events/100 patient-years]. The risk of serious infections increased in patients who had a history of malignancy and those with concomitant corticosteroid use. Of 415 patients who had switched from another anti-tumour necrosis factor alpha [TNFα] agent to adalimumab due to ADRs, 7.2{\%} discontinued due to ADRs to adalimumab. Ten of 13 patients with a history of tuberculosis [TB] received prophylactic medication, and none developed TB. TB developed in one patient with no history of TB or anti-TB prophylaxis. Remission rates were 41.3{\%} and 32.4{\%} at 4 and 24 weeks, respectively. Remission rates did not differ between patients with and without concomitant use of immunomodulators. Predictive variables for increased effectiveness were CDAI ≤ 220 and disease duration of ≤ 2 years. Perianal lesions and loss of response to previous anti-TNFα agents affected effectiveness. Conclusions: The most frequent serious ADR was infection. Adalimumab significantly reduced disease activity, without any unexpected ADRs. Development of active TB during adalimumab therapy can be prevented through TB screening and prophylaxis. In patients who switched from another anti-TNFα agent to adalimumab due to ADRs, adalimumab was well tolerated.",
keywords = "Adalimumab, Crohn's disease, Post-marketing study",
author = "Haruhiko Ogata and Mamoru Watanabe and Toshiyuki Matsui and Hidenori Hase and Motohiro Okayasu and Tsuyoshi Tsuchiya and Yasuhiko Shinmura and Toshifumi Hibi",
year = "2016",
doi = "10.1093/ecco-jcc/jjw060",
language = "English",
volume = "10",
pages = "1033--1041",
journal = "Journal of Crohn's and Colitis",
issn = "1873-9946",
publisher = "Elsevier",
number = "9",

}

TY - JOUR

T1 - Safety of adalimumab and predictors of adverse events in 1693 Japanese patients with Crohn's disease

AU - Ogata, Haruhiko

AU - Watanabe, Mamoru

AU - Matsui, Toshiyuki

AU - Hase, Hidenori

AU - Okayasu, Motohiro

AU - Tsuchiya, Tsuyoshi

AU - Shinmura, Yasuhiko

AU - Hibi, Toshifumi

PY - 2016

Y1 - 2016

N2 - Background and Aims: Data from an all-cases post-marketing study were used to evaluate the safety and effectiveness of adalimumab in Japanese patients with Crohn's disease [CD]. Methods: Patients received adalimumab for 24 weeks. Data from all patients [n = 1693] were used for the safety assessment. Data from patients with CD activity index [CDAI] ≥ 150 at baseline were used for the effectiveness assessment. Results: The most frequent serious adverse drug reaction [ADR] was infection and infestations [6.6 events/100 patient-years]. The risk of serious infections increased in patients who had a history of malignancy and those with concomitant corticosteroid use. Of 415 patients who had switched from another anti-tumour necrosis factor alpha [TNFα] agent to adalimumab due to ADRs, 7.2% discontinued due to ADRs to adalimumab. Ten of 13 patients with a history of tuberculosis [TB] received prophylactic medication, and none developed TB. TB developed in one patient with no history of TB or anti-TB prophylaxis. Remission rates were 41.3% and 32.4% at 4 and 24 weeks, respectively. Remission rates did not differ between patients with and without concomitant use of immunomodulators. Predictive variables for increased effectiveness were CDAI ≤ 220 and disease duration of ≤ 2 years. Perianal lesions and loss of response to previous anti-TNFα agents affected effectiveness. Conclusions: The most frequent serious ADR was infection. Adalimumab significantly reduced disease activity, without any unexpected ADRs. Development of active TB during adalimumab therapy can be prevented through TB screening and prophylaxis. In patients who switched from another anti-TNFα agent to adalimumab due to ADRs, adalimumab was well tolerated.

AB - Background and Aims: Data from an all-cases post-marketing study were used to evaluate the safety and effectiveness of adalimumab in Japanese patients with Crohn's disease [CD]. Methods: Patients received adalimumab for 24 weeks. Data from all patients [n = 1693] were used for the safety assessment. Data from patients with CD activity index [CDAI] ≥ 150 at baseline were used for the effectiveness assessment. Results: The most frequent serious adverse drug reaction [ADR] was infection and infestations [6.6 events/100 patient-years]. The risk of serious infections increased in patients who had a history of malignancy and those with concomitant corticosteroid use. Of 415 patients who had switched from another anti-tumour necrosis factor alpha [TNFα] agent to adalimumab due to ADRs, 7.2% discontinued due to ADRs to adalimumab. Ten of 13 patients with a history of tuberculosis [TB] received prophylactic medication, and none developed TB. TB developed in one patient with no history of TB or anti-TB prophylaxis. Remission rates were 41.3% and 32.4% at 4 and 24 weeks, respectively. Remission rates did not differ between patients with and without concomitant use of immunomodulators. Predictive variables for increased effectiveness were CDAI ≤ 220 and disease duration of ≤ 2 years. Perianal lesions and loss of response to previous anti-TNFα agents affected effectiveness. Conclusions: The most frequent serious ADR was infection. Adalimumab significantly reduced disease activity, without any unexpected ADRs. Development of active TB during adalimumab therapy can be prevented through TB screening and prophylaxis. In patients who switched from another anti-TNFα agent to adalimumab due to ADRs, adalimumab was well tolerated.

KW - Adalimumab

KW - Crohn's disease

KW - Post-marketing study

UR - http://www.scopus.com/inward/record.url?scp=85012254730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012254730&partnerID=8YFLogxK

U2 - 10.1093/ecco-jcc/jjw060

DO - 10.1093/ecco-jcc/jjw060

M3 - Article

C2 - 26961546

AN - SCOPUS:85012254730

VL - 10

SP - 1033

EP - 1041

JO - Journal of Crohn's and Colitis

JF - Journal of Crohn's and Colitis

SN - 1873-9946

IS - 9

ER -